Opioid Analgesic Deprescribing

Chronic opioid exposure causes receptor downregulation, paradoxical opioid-induced hyperalgesia (OIH), and HPA axis suppression. Structured dose reduction reverses these adaptations, often improving pain sensitivity, mood, and function over 6–12 months. Buprenorphine transition is often preferred over direct taper due to its analgesic ceiling and anti-hyperalgesic properties.

Rate: no single schedule suits everyone, so the size and interval of each step are individualised; in practice a step might be as small as 5% or as large as 50% of the current dose. Go slower after long-term or high-dose use; go faster only where safety requires it (for example after an overdose); opioids used for less than about a week, or only infrequently, can be stopped without a taper. Pause the taper if significant withdrawal or a decline in function appears, then review. Buprenorphine rotation: high mu-opioid affinity displaces other opioids; use micro-induction or Bernese method to avoid precipitated withdrawal. Adjuncts during taper:

• Clonidine or lofexidine (autonomic symptoms: sweating, agitation, hypertension)
• Low-dose naltrexone (OIH reversal)
• Duloxetine or pregabalin (neuropathic pain component)
• NSAIDs (non-opioid analgesia bridging)
• Psychological support: CBT, ACT, pain management programme

Australian guideline (Langford et al., Med J Aust 2023; GRADE-based): recommends gradual tapering and tailoring the plan to the person's clinical characteristics, goals and preferences, and suggests regular monitoring and review throughout. It does not prescribe a fixed schedule: the rate may need to be slower after long-term or high-dose use, faster tapers or cessation may be needed for safety (for example after an overdose), opioids used for less than about a week or only infrequently may be stopped without a taper, and the taper can be paused if significant withdrawal or a decline in function occurs. It suggests interdisciplinary or multidisciplinary care, or a multimodal approach, when available, and rates the evidence that opioids can be reduced without worsening pain as very low to low certainty. Systematic reviews: Frank et al. (Ann Intern Med 2017) found very low quality evidence that several types of intervention may help reduce or stop long-term opioid therapy, and that pain, function and quality of life may improve with dose reduction; the Cochrane review (Eccleston et al. 2017) found only five small trials with mixed results and no evidence yet for the efficacy or safety of reduction methods.

• Abrupt cessation without prior dose reduction may increase the risk of harm, and a taper that is too fast can precipitate severe withdrawal and increase dropout; match the pace to the person
• Monitor for opioid use disorder (DSM-5 criteria), other substance use and overdose risk before and throughout the taper. The Australian guideline notes emerging evidence that precipitous or involuntary tapering may increase substance use, overdose and suicide, and suggests avoiding deprescribing in severe opioid use disorder, with evidence-based care provided instead, such as transition to, or referral for, medication-assisted treatment (in Victoria, opioid dependence treatment (ODT), also called opioid substitution therapy (OST)). Pharmacotherapy cards: buprenorphine/naloxone sublingual, buprenorphine long-acting injectable, buprenorphine transdermal patch and methadone.
• Monitor for suicidality during dose reduction (opioid withdrawal worsens mood significantly)
• Avoid concurrent benzodiazepine use if possible: compound respiratory risk
• Document capacity, consent, and clinical reasoning: medico-legal context
• Buprenorphine transition requires COWS scoring and careful timing to avoid precipitated withdrawal
• Do not set rigid timelines: individualise to patient response and psychosocial context